TEM
NASDAQ · Life Sciences Tools & Services
Tempus Ai Inc
$78.03
+0.19 (+0.24%)
TEM News11 articles
Tempus AI's Cancer Platform: Evidence, Limits, and What It Means for Investors
Tempus AI's cancer-care platform integrates molecular and clinical data to support oncologists. While recent studies show promising results, the evidence falls short of proving the platform improves patient survival.
Tempus AI Surges 10.7% on $200M Data-Licensing Bookings
Tempus AI (TEM) shares surged 10.7% after management revealed $200 million in new data-licensing contracts, highlighting strong AI-driven demand. Investors weigh this momentum against diagnostic pricing challenges.
Doximity Soars 32% on AI Optimism Despite Soft Profit Outlook
Doximity shares surged 32.5% on Friday, boosting market cap by $1.2B, as investors focused on AI potential despite weaker profit guidance and mixed Q1 results.
Tempus AI Dips After Hours Despite Q2 Beat; Focus Shifts to H2 Profitability
Tempus AI slipped 2.6% in after-hours trade despite a slight Q2 revenue beat and raised full-year guidance, as markets scrutinize the company's ability to ramp margins in the second half.
Tempus AI Shares Tumble 19% as Personalis Deal Terms Come Under Scrutiny
Tempus AI shares dropped nearly 19% over the past week, closing at $42.69 and falling below both reference points in its proposed acquisition of Personalis.
Personalis Shares Slide on Tempus's $16.25 Bid, Meager 6% Premium Sparks Concerns
Personalis shares dropped 11.6% despite a $16.25 acquisition bid from Tempus AI, as the modest 6% premium and stock-based structure fueled investor skepticism.
Tempus AI Shares Near Deal Termination Threshold After 7.8% Drop
Tempus AI shares dropped 7.8% to $48.39, nearing the $46 threshold that could trigger a termination right for Personalis, wiping $730 million from market cap.
Tempus AI Upsizes Convertible Debt to $400M, Eyes Loan Repayment
Tempus AI priced $400M in 0% convertible senior notes, using proceeds to repay $307.7M in loans. Shares fell 7.6% premarket despite strong Q1 revenue growth.
Tempus AI Faces Pivotal May with Q1 Results and Inaugural Investor Day
Tempus AI reports Q1 results May 5 and holds its first investor day May 29, with Merck CEO highlighting the partnership. Stock trades near $55.44 with a $9.7B market cap.
Tempus AI Partners with USC Health System, Unlocking Access to 1.5 Million Annual Visits
Tempus AI Inc. partners with USC's Keck School of Medicine to deploy its molecular testing and trial-matching platform across a health system seeing 1.5 million patient visits each year.
Tempus AI Stock Drops on USC Partnership as Cancer Data Strategy Faces Scrutiny
Tempus AI shares fell 7.3% after announcing a partnership with USC to deploy its molecular testing and AI tools across the health system, covering over 1.5 million annual patient visits.